4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · IEX Real-Time Price · USD
14.40
-0.74 (-4.89%)
At close: Jul 19, 2024, 4:00 PM
14.55
+0.15 (1.04%)
Pre-market: Jul 22, 2024, 7:29 AM EDT
4D Molecular Therapeutics Revenue
4D Molecular Therapeutics had revenue of $20.45M in the twelve months ending March 31, 2024, with 826.69% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $28.00K. In the year 2023, 4D Molecular Therapeutics had annual revenue of $20.72M with 562.29% growth.
Revenue (ttm)
$20.45M
Revenue Growth
+826.69%
P/S Ratio
36.40
Revenue / Employee
$139,129
Employees
147
Market Cap
744.53M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 20.72M | 17.59M | 562.29% |
Dec 31, 2022 | 3.13M | -14.91M | -82.65% |
Dec 31, 2021 | 18.04M | 4.43M | 32.52% |
Dec 31, 2020 | 13.61M | 6.63M | 94.85% |
Dec 31, 2019 | 6.99M | -7.14M | -50.56% |
Dec 31, 2018 | 14.13M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Embecta | 1.13B |
Phibro Animal Health | 999.56M |
Evolus | 219.70M |
Travere Therapeutics | 183.23M |
Sage Therapeutics | 91.06M |
Lexicon Pharmaceuticals | 2.31M |
Pliant Therapeutics | 248.00K |
FDMT News
- 15 hours ago - 4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - Business Wire
- 21 hours ago - FDMT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Investors to Contact the Firm! - Accesswire
- 2 days ago - FDMT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Investors to Contact the Firm! - Accesswire
- 2 days ago - 4D Molecular Therapeutics Inc Stakeholders Are Welcomed By The Schall Law Firm To Participate In The Securities Fraud Probe - Accesswire
- 2 days ago - FDMT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Investors to Contact the Firm! - Accesswire
- 3 days ago - The Schall Law Firm Invites FDMT Investors To Join The Securities Fraud Investigation Of 4D Molecular Therapeutics Inc. - Accesswire
- 4 days ago - Investors In FDMT Are Invited To Participate In The Securities Fraud Investigation Of 4D Molecular Therapeutics Inc Conducted By The Schall Law Firm - Accesswire
- 4 days ago - FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - Business Wire